- Home
- ACCD
ACCD
Accolade Inc.
as 03-25-2025 11:30am EST
Accolade Inc offers technology-enabled solutions that help people understand, navigate, and utilize the healthcare system and their workplace benefits. The company's platform combines open, cloud-based intelligent technology with multimodal support from a team of Accolade Care Advocates and clinicians, including registered nurses, physician medical directors, pharmacists, primary care physicians, and other professionals to provide advocacy, medical opinion, and virtual primary care services.
| Founded: | 2007 | Country: | United States |
| Employees: | N/A | City: | PLYMOUTH MEETING |
| Market Cap: | 569.3M | IPO Year: | 2020 |
| Target Price: | $6.22 | AVG Volume (30 days): | 997.3K |
| Analyst Decision: | Hold | Number of Analysts: | 11 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.31 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.08 - $10.68 | Next Earning Date: | 04-24-2025 |
| Revenue: | $446,718,000 | Revenue Growth: | 14.99% |
| Revenue Growth (this year): | 14.47% | Revenue Growth (next year): | 12.51% |
Stock Insider Trading Activity of Accolade Inc. (ACCD)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Cavanaugh Robert N | ACCD | President | Mar 17 '25 | Sell | $6.99 | 181 | $1,264.29 | 218,697 | |
| SINGH RAJEEV | ACCD | Chief Executive Officer | Mar 17 '25 | Sell | $6.99 | 289 | $2,018.67 | 829,090 | |
| Cavanaugh Robert N | ACCD | President | Mar 10 '25 | Sell | $6.97 | 249 | $1,734.28 | 218,697 | |
| SINGH RAJEEV | ACCD | Chief Executive Officer | Mar 10 '25 | Sell | $6.97 | 490 | $3,412.85 | 829,090 | |
| Barnes Stephen H. | ACCD | Chief Financial Officer | Mar 10 '25 | Sell | $6.97 | 254 | $1,769.11 | 303,761 | |
| Cavanaugh Robert N | ACCD | President | Mar 3 '25 | Sell | $6.96 | 550 | $3,828.00 | 218,697 | |
| SINGH RAJEEV | ACCD | Chief Executive Officer | Mar 3 '25 | Sell | $6.96 | 1,121 | $7,802.16 | 829,090 | |
| Eskew Richard | ACCD | EVP General Counsel | Mar 3 '25 | Sell | $6.96 | 377 | $2,623.92 | 64,784 | |
| Barnes Stephen H. | ACCD | Chief Financial Officer | Mar 3 '25 | Sell | $6.96 | 514 | $3,577.44 | 303,761 | |
| Cavanaugh Robert N | ACCD | President | Feb 18 '25 | Sell | $6.90 | 180 | $1,242.18 | 218,697 |
Latest Accolade Inc. News
ACCD Breaking Stock News: Dive into ACCD Ticker-Specific Updates for Smart Investing
Zacks
12 days ago
Do Options Traders Know Something About Accolade (ACCD) Stock We Don't?
PR Newswire
19 days ago
Accolade Welcomes Oshi Health to Trusted Partner Ecosystem
Investing.com
20 days ago
Piper Sandler downgrades Accolade ahead of shareholder vote
MT Newswires
20 days ago
Piper Sandler Downgrades Accolade to Neutral From Overweight, $9 Price Target
Zacks
21 days ago
Has Accolade (ACCD) Outpaced Other Business Services Stocks This Year?
GlobeNewswire
a month ago
Transcarent and Accolade Announce Expiration of Hart-Scott Rodino Waiting Period for Pending Merger Transaction
PR Newswire
2 months ago
Accolade Expands Virtual Care to Medicare Beneficiaries Nationwide Through PlushCare Direct-to-Consumer Offering
Insider Monkey
2 months ago
Why Accolade Inc (ACCD) Is Skyrocketing So Far In 2025
Compare ACCD vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ACCD Accolade Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.